{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:14:03Z","timestamp":1761059643452},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:00:00Z","timestamp":1386892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s11906-013-0410-z","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T01:53:30Z","timestamp":1386813210000},"source":"Crossref","is-referenced-by-count":14,"title":["The Glycemic Effects of Antihypertensive Medications"],"prefix":"10.1007","volume":"16","author":[{"given":"Joshua I.","family":"Barzilay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul K.","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"410_CR1","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","volume":"346","author":"T Gomes","year":"2013","unstructured":"Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.","journal-title":"BMJ"},{"key":"410_CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/157016108785909715","volume":"6","author":"G Muscogiuri","year":"2008","unstructured":"Muscogiuri G, Chavez AO, Gastaldelli A, Perego L, Tripathy D, Saad MJ, et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol. 2008;6:301\u201312.","journal-title":"Curr Vasc Pharmacol"},{"key":"410_CR3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1262-3636(07)70147-7","volume":"30","author":"AJ Scheen","year":"2004","unstructured":"Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 2004;30:498\u2013505.","journal-title":"Diabetes Metab"},{"key":"410_CR4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/HYPERTENSIONAHA.108.119438","volume":"52","author":"T Shafi","year":"2008","unstructured":"Shafi T, Appel LJ, Miller 3rd ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022\u20139.","journal-title":"Hypertension"},{"key":"410_CR5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00129784-200606030-00001","volume":"6","author":"TA Aksnes","year":"2006","unstructured":"Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines? Am J Cardiovasc Drugs. 2006;6:139\u201347.","journal-title":"Am J Cardiovasc Drugs"},{"key":"410_CR6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/DMSO.S49767","volume":"6","author":"H Noto","year":"2013","unstructured":"Noto H, Goto A, Tsujimoto T, Noda M. Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes. 2013;6:257\u201361.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"410_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCOUTCOMES.112.965046","volume":"5","author":"RR Lleva","year":"2012","unstructured":"Lleva RR, Inzucchi SE. Glucose, blood pressure, and cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2012;5:145\u20137. An informative review of the effects of anti-hypertensive medications on glucose metabolism.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"410_CR8","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","volume":"286","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Gerstein H, Hoogwerf B, et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882\u20135.","journal-title":"JAMA"},{"key":"410_CR9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","volume":"362","author":"RR Holman","year":"2010","unstructured":"Holman RR, Haffner SM, McMurray JJ, et al. NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463\u201376.","journal-title":"N Engl J Med"},{"key":"410_CR10","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","volume":"355","author":"J Bosch","year":"2006","unstructured":"Bosch J, Yusuf S, Gerstein HC, et al. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551\u201362.","journal-title":"N Engl J Med"},{"key":"410_CR11","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/dc11-0545","volume":"34","author":"JI Barzilay","year":"2011","unstructured":"Barzilay JI, Gao P, Ryd\u00e9n L, Schumacher H, Probstfield J, Commerford P, et al. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: The TRANSCEND Study. Diabetes Care. 2011;34:1902\u20137.","journal-title":"Diabetes Care"},{"key":"410_CR12","unstructured":"European Society of Hypertension-European Society of Cardiology. 2013 Guidelines for the management of arterial hypertension. Available at: http:\/\/www.escardio.org\/guidelines-surveys\/esc-guidelines\/Pages\/arterial-hypertension.aspx"},{"key":"410_CR13","volume-title":"Management of Hypertension in Adults with Primary Care \u2013 Partial Update","author":"NICE Hypertension","year":"2006","unstructured":"Hypertension NICE. Management of Hypertension in Adults with Primary Care \u2013 Partial Update. London: National Institute of Health and Clinical Excellence; 2006."},{"key":"410_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2337\/diacare.27.1.247","volume":"27","author":"R Padwal","year":"2004","unstructured":"Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. A systemic review. Diabetes Care. 2004;27:247\u201355. A review of anti-hypertension studies and the effects of medications on glycemia.","journal-title":"Diabetes Care"},{"issue":"9557","key":"410_CR15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201\u20137. A review of anti-hypertension studies and the effects of medications on glycemia.","journal-title":"Lancet"},{"key":"410_CR16","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981\u201397.","journal-title":"JAMA"},{"key":"410_CR17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"JI Barzilay","year":"2006","unstructured":"Barzilay JI, Davis BR, Cutler J, et al. Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to three different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191\u2013201.","journal-title":"Arch Intern Med"},{"key":"410_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","volume":"95","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29\u201335.","journal-title":"Am J Cardiol"},{"key":"410_CR19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/bmj.313.7058.660","volume":"313","author":"O Samuelsson","year":"1996","unstructured":"Samuelsson O, Pennert K, Andersson O, et al. Diabetes mellitus and raised serum triglyceride concentration in treated hypertension: are they of prognostic importance? observational study. BMJ. 1996;313:660\u20133.","journal-title":"BMJ"},{"key":"410_CR20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","volume":"321","author":"The Cardiac Arrhythmia Suppression Trial (CAST) Investigators","year":"1989","unstructured":"The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406\u201312.","journal-title":"N Engl J Med"},{"key":"410_CR21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0026-0495(80)90074-8","volume":"29","author":"JW Rowe","year":"1980","unstructured":"Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism. 1980;29:498\u2013502.","journal-title":"Metabolism"},{"key":"410_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCOUTCOMES.111.962522","volume":"5","author":"JI Barzilay","year":"2012","unstructured":"Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, et al. ALLHAT Collaborative Research Group. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcome. 2012;5:153\u201362. A 10-year follow-up of ALLHAT and the effects of incident diabetes associated with the three antihypertensive medications used during the trial on CVD outcomes.","journal-title":"Circ Cardiovasc Qual Outcome"},{"key":"410_CR23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"410_CR24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2840-9-21","volume":"9","author":"B Kveiborg","year":"2010","unstructured":"Kveiborg B, Hermann TS, Major-Pedersen A, Christiansen B, Rask-Madsen C, Rauns\u00f8 J, et al. Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes\u2014a randomized study. Cardiovasc Diabetol. 2010;9:21.","journal-title":"Cardiovasc Diabetol"},{"key":"410_CR25","unstructured":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713\u2013720."},{"key":"410_CR26","doi-asserted-by":"crossref","unstructured":"A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983; 250: 2814\u20132819.","DOI":"10.1001\/jama.1983.03340200048027"},{"key":"410_CR27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199808203390801","volume":"339","author":"SS Gottlieb","year":"1998","unstructured":"Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489\u201397.","journal-title":"N Engl J Med"},{"key":"410_CR28","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0735-1097(99)00383-6","volume":"34","author":"J Chen","year":"1999","unstructured":"Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol. 1999;34:1388\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"410_CR29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","volume":"342","author":"TW Gress","year":"2000","unstructured":"Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905\u201312.","journal-title":"N Engl J Med"},{"key":"410_CR30","first-page":"257","volume":"8","author":"O Samuelsson","year":"1994","unstructured":"Samuelsson O, Hedner T, Berglund G, Persson B, Andersson OK, Wilhelmsen L. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15\u00a0years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 1994;8:257\u201363.","journal-title":"J Hum Hypertens"},{"key":"410_CR31","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.2337\/diacare.27.10.2458","volume":"27","author":"R Padwal","year":"2004","unstructured":"Padwal R, Mamdani M, Alter DA, Hux JE, Rothwell DM, Tu K, et al. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care. 2004;27:2458\u201363.","journal-title":"Diabetes Care"},{"key":"410_CR32","doi-asserted-by":"crossref","unstructured":"Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Hypertension 1985; 7(6 Pt 1):1008\u20131016.","DOI":"10.1161\/01.HYP.7.6.1008"},{"key":"410_CR33","unstructured":"Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981; 2(8246): 539\u2013543."},{"key":"410_CR34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0002-9343(84)90990-2","volume":"76","author":"A Helgeland","year":"1984","unstructured":"Helgeland A, Leren P, Foss OP, Hjermann I, Holme I, Lund-Larsen PG. Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. The Oslo study. Am J Med. 1984;76:802\u20135.","journal-title":"Am J Med"},{"key":"410_CR35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archinte.158.7.741","volume":"158","author":"PJ Savage","year":"1998","unstructured":"Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158:741\u201351.","journal-title":"Arch Intern Med"},{"key":"410_CR36","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1001\/jama.292.23.2849","volume":"292","author":"S Wassertheil-Smoller","year":"2004","unstructured":"Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, Kotchen T, Mouton C, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292:2849\u201359.","journal-title":"JAMA"},{"key":"410_CR37","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/HCO.0b013e32836429e6","volume":"28","author":"CM Minder","year":"2013","unstructured":"Minder CM, Blumenthal RS, Blaha MJ. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol. 2013;28:554\u201360.","journal-title":"Curr Opin Cardiol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-013-0410-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-013-0410-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-013-0410-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T16:38:52Z","timestamp":1564936732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-013-0410-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,13]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1007\/s11906-013-0410-z","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,13]]},"article-number":"410"}}